rinatabart sesutecan

AssetAlso Rina-S, Rina-S®, RAINFOLTM-01

Folate receptor alpha (FOLR1)-directed antibody-drug conjugate.

Stage: Phase 2
Modality: Antibody
Target: DNA damage response; 1
Indication: 0
Trials: 1
Developer

Indications

1

Platinum-resistant ovarian cancer
Phase 2, businesswire.com, 3 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Evidence for its targets2
Competitors12
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 2 sources